Since different AD phenotypes show distinct patterns of tau pathology,5,16,20,39-43 our findings support the use of individualized ROIs rather than one-size-fits-all approaches when tau-PET is used as an outcome measure.99 Patient-specific ROIs tailored to functional connectivity and tau pathology patterns could improve trial sensitivity, enhance the detection of treatment effects and ultimately increase the likelihood of successful therapeutic outcomes. Here, MAPT is linked to Alzheimer disease.